Synaptogenix

Synaptogenix, Inc. operates as a biopharmaceutical company with product candidates in pre-clinical and clinical development. It focuses on developing a product platform based upon a drug candidate called Bryostatin-1 for the treatment of Alzheimer's disease. The company is also evaluating therapeutic applications of bryostatin for other neurodegenerative or cognitive diseases and dysfunctions, such as fragile X syndrome, multiple sclerosis, and Niemann-pick type C disease. Synaptogenix, Inc. has licensing agreements with Stanford University; Icahn School of Medicine at Mount Sinai; and The Board of Trustees of the Leland Stanford Junior University. The company was incorporated in 2012 and is headquartered in New York, New York.

To develop innovative treatments and medications to improve the lives of those suffering from neurodegenerative diseases.

To be a leader in the field of innovative treatments, medications and products for neurodegenerative diseases.

Synaptogenix has won multiple awards and commendations, including the 2018 Mobile Planet Award, the 2017 International Technology Innovation Award, and the 2016 Top 10 Innovators Award, among others.